NEW YORK (GenomeWeb) – Hibergene said last week that it has received CE marking for its HG Meningococcus Direct CSF test and launched it.
The test leverages loop mediated isothermal amplification technology and enables the rapid detection of Neisseria meningitidis, a leading cause of bacterial meningitis, directly from cerebrospinal fluid samples in less than 50 minutes. It can detect all known Neisseria meningitidis serogroups, including A, B, C, 29E, W135, X, Y, and Z at low levels with high accuracy, the Dublin-based firm said in a statement.
"HiberGene is building a portfolio of rapid molecular tests for a range of life-threatening diseases that are capable of saving lives and reducing healthcare costs," HiberGene CEO Brendan Farrell said in a statement, adding the development of the HG Meningococcus Direct CSF test "demonstrates how advances in technology can provide clinically important results in a matter of minutes to deliver significant improvements in patient care."